Agile Therapeutics. has been granted a patent for a transdermal drug delivery device designed to minimize skin irritation and detachment during a seven-day wear period. The device features a specialized polymer matrix and a unique manufacturing process to enhance the stability of active ingredients. GlobalData’s report on Agile Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Agile Therapeutics, was a key innovation area identified from patents. Agile Therapeutics's grant share as of July 2024 was 40%. Grant share is based on the ratio of number of grants to total number of patents.
Transdermal drug delivery device with specific irritation properties
The granted patent US12070520B2 outlines a novel process for creating a non-heat sealed transdermal drug delivery device. This device features a polymer matrix active ingredient (AI) layer that includes a pressure-sensitive adhesive (PSA) made from polyacrylate, along with at least one volatile component that is partially solubilized in the PSA. The device is structured with a release liner in direct contact with the skin-contacting surface of the AI layer, and an overlay adjacent to the non-skin contacting surface, which consists of a polyisobutylene PSA layer. The design ensures that the release liner and the overlay's PSA layer are adhered around the perimeter of the AI layer, forming a seal that minimizes the loss of volatile components from the AI layer.
The process for manufacturing this device involves determining the solubility of the volatile components in both the AI layer's PSA and the overlay's PSA. The selection of PSAs is based on achieving a greater solubility of the volatile component in the AI layer compared to the overlay, or vice versa. The manufacturing steps include creating a laminate of the internal backing, AI layer, and release liner, followed by the application of the overlay to complete the drug delivery device. The patent also specifies various examples of volatile components that can be used, including sulfoxides, alcohols, fatty acids, and organic acids, among others. This innovative approach aims to enhance the efficacy and stability of transdermal drug delivery systems.
To know more about GlobalData’s detailed insights on Agile Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
